Gilead Sciences Inc.

02/12/2026 | Press release | Distributed by Public on 02/12/2026 18:27

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Cain Wettan Keeley M
2. Date of Event Requiring Statement (Month/Day/Year)
02/04/2026
3. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [GILD]
(Last) (First) (Middle)
333 LAKESIDE DRIVE
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP Gen Counsel, Legal & Comp
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
FOSTER CITY, CA 94404
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,944 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) (1) Common Stock 5,440 (2) D
Restricted Stock Unit (3) (3) Common Stock 11,342 (2) D
Non-qualified Stock Option (Right to Buy) (4) 03/10/2032 Common Stock 3,072 $57.92 D
Non-qualified Stock Option (Right to Buy) (4) 03/10/2033 Common Stock 4,412 $79.5 D
Non-qualified Stock Option (Right to Buy) (4) 03/10/2034 Common Stock 6,996 $75.12 D
Non-qualified Stock Option (Right to Buy) (4) 03/10/2035 Common Stock 5,140 $117.21 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Cain Wettan Keeley M
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404
EVP Gen Counsel, Legal & Comp

Signatures

/s/ Edward S. Son by Power of Attorney for Keeley M. Cain Wettan 02/12/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance vest 6.25% quarterly thereafter until fully vested.
(2) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
(3) The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.
(4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance vest 6.25% quarterly thereafter until fully vested.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Gilead Sciences Inc. published this content on February 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 13, 2026 at 00:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]